Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 3Genitourinary 2Tumor-Agnostic 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer 1Disease 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × vistusertib × Genitourinary × Clear all
NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting
117 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed
23 enrolled
Genitourinary

Disease, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡